Target intelligence / Profile preview

Intraflagellar transport protein 20 homolog (IFT20)

Target: IFT20
Molecular classification: Other (Ciliary transport protein/IFT complex B subunit)

Overview

Intraflagellar transport protein 20 homolog (IFT20) is a small, highly conserved protein that is an integral component of the IFT complex B, which is essential for the assembly and maintenance of eukaryotic cilia and flagella[1][2][5]. IFT20 is unique among IFT proteins for its dual localization at both the cilium/basal body and the Golgi apparatus, acting as a dynamic adapter to facilitate trafficking of ciliary membrane proteins from the Golgi to the cilium. It is anchored to the Golgi via GMAP-210, and its function includes assembling IFT "trains" within the cilium, as well as mediating protein transport to the ciliary compartment[4][5]. IFT20 is implicated in cellular processes beyond ciliogenesis, notably in immune cell signaling (especially T cell activation) and regulation of receptor trafficking linked to cell migration and tumor invasiveness[4][5]. Defects in IFT20 are associated with a variety of ciliopathies and have roles in tumorigenesis and immune modulation, though it is not currently considered a direct drug target.

Other names: Intraflagellar transport 20IFT20hIFT20intraflagellar transport protein IFT20intraflagellar transport protein 20 homolog

Mechanism of action

Not applicable. No drugs currently target IFT20 for a defined mechanism of action[5].

Biological functions

Ciliary assembly and maintenance[1][2][5]Vesicular trafficking (Golgi to cilia)[1][5]Trafficking of ciliary membrane proteins[1][4][5]Centrosome and basal body association[4][5]T cell receptor signaling in immune synapses (cilia-independent function)[4][5]Regulation of receptor (PDGFRα, ROR2) localization and signaling[5][4]

Disease associations

Ciliopathies (defects in ciliary assembly/function)[2][5]Immune dysfunction (T cell signaling)[4][5]Cancer (regulation of tumor cell migration and invasiveness)[4][5]

Safety considerations

Not applicable. As IFT20 is not a direct drug target, safety concerns relate to genetic disruption (e.g. loss of cilia, immune or developmental defects) rather than therapeutic intervention[5].

Beyond the preview

Go deeper on Intraflagellar transport protein 20 homolog (IFT20).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intraflagellar transport protein 20 homolog (IFT20).

Explore the full profile